Synlogic (SYBX) Competitors $1.09 -0.07 (-6.03%) As of 01:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. OKUR, CUE, APLT, PMVP, VTVT, CNTX, ALTS, IMRX, BYSI, and STROShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include OnKure Therapeutics (OKUR), Cue Biopharma (CUE), Applied Therapeutics (APLT), PMV Pharmaceuticals (PMVP), vTv Therapeutics (VTVT), Context Therapeutics (CNTX), Janone (ALTS), Immuneering (IMRX), BeyondSpring (BYSI), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. OnKure Therapeutics Cue Biopharma Applied Therapeutics PMV Pharmaceuticals vTv Therapeutics Context Therapeutics Janone Immuneering BeyondSpring Sutro Biopharma Synlogic (NASDAQ:SYBX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations. Does the media refer more to SYBX or OKUR? In the previous week, OnKure Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for OnKure Therapeutics and 0 mentions for Synlogic. OnKure Therapeutics' average media sentiment score of 1.73 beat Synlogic's score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Synlogic Neutral OnKure Therapeutics Very Positive Do analysts recommend SYBX or OKUR? OnKure Therapeutics has a consensus price target of $32.33, indicating a potential upside of 858.02%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has higher valuation and earnings, SYBX or OKUR? Synlogic has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,593.58-$57.28M-$2.51-0.43OnKure TherapeuticsN/AN/A-$77.39M-$6.57-0.51 Does the MarketBeat Community believe in SYBX or OKUR? Synlogic received 324 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% OnKure TherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Which has more volatility & risk, SYBX or OKUR? Synlogic has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SYBX or OKUR? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is SYBX or OKUR more profitable? OnKure Therapeutics' return on equity of -51.17% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% OnKure Therapeutics N/A -51.17%-47.11% SummaryOnKure Therapeutics beats Synlogic on 11 of the 17 factors compared between the two stocks. Remove Ads Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.57M$6.72B$5.53B$7.50BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-0.286.9923.2218.08Price / Sales1,695.92198.60363.0886.83Price / CashN/A65.6738.1634.64Price / Book0.255.926.493.99Net Income-$57.28M$142.37M$3.21B$247.18M7 Day Performance-9.38%-7.24%-4.91%-4.25%1 Month Performance-11.45%-10.45%-0.08%-6.87%1 Year Performance-35.20%-14.58%6.40%-3.73% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogicN/A$1.09-6.0%N/A-35.2%$12.75M$8,000.00-0.2680Gap DownOKUROnKure Therapeutics3.3098 of 5 stars$4.30-3.6%$32.33+651.9%N/A$57.78MN/A-0.35N/APositive NewsGap DownCUECue Biopharma4.3519 of 5 stars$0.91-1.0%$4.75+421.4%-57.0%$57.71M$9.53M-1.0160Earnings ReportAPLTApplied Therapeutics3.9762 of 5 stars$0.49-5.1%$6.10+1,144.9%-93.4%$57.01M$-212,000.00-0.3030PMVPPMV Pharmaceuticals1.7257 of 5 stars$1.09-1.8%$5.50+404.6%-41.5%$56.61MN/A-1.0950Gap DownVTVTvTv Therapeutics1.4949 of 5 stars$17.32-0.2%$35.00+102.1%-30.3%$55.25M$1.02M-3.829Gap DownCNTXContext Therapeutics1.9665 of 5 stars$0.61-6.6%$6.17+907.6%-42.0%$54.90MN/A-0.677Gap DownALTSJanoneN/A$3.88-6.1%N/AN/A$54.59M$7.11M0.00170Short Interest ↓IMRXImmuneering3.3064 of 5 stars$1.52-7.3%$11.00+623.7%-37.1%$54.55M$320,000.00-0.7760Short Interest ↓Positive NewsGap DownBYSIBeyondSpringN/A$1.39-3.8%N/A-53.4%$54.09M$1.88M0.0080Gap DownSTROSutro Biopharma3.8038 of 5 stars$0.65-11.7%$6.63+918.3%-88.4%$53.65M$62.04M-0.40240Gap Down Remove Ads Related Companies and Tools Related Companies OnKure Therapeutics Competitors Cue Biopharma Competitors Applied Therapeutics Competitors PMV Pharmaceuticals Competitors vTv Therapeutics Competitors Context Therapeutics Competitors Janone Competitors Immuneering Competitors BeyondSpring Competitors Sutro Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYBX Stock Free SYBX Stock Alerts